Navigation Links
Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial
Date:5/14/2008

CAMBRIDGE, Mass., May 14 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) today announced that the results from its Phase II coronary revascularization trial have been published in the peer-reviewed EuroIntervention Journal. The paper is entitled "Proof-of-concept trial to evaluate haemoglobin based oxygen therapeutics in elective percutaneous coronary revascularization. Rationale, protocol design, and haemodynamic results." The manuscript was authored by principal investigator Patrick W. Serruys, MD, PhD and colleagues of the Department of Interventional Cardiology, Thoraxcenter, Erasmus MC, University Medical Centre Rotterdam, The Netherlands.

"Biopure's COR-0002 study in the EuroIntervention Journal demonstrates the potential use of Hemopure (HBOC-201) in patients with coronary artery disease," said Biopure Chairman and CEO Zafiris G. Zafirelis. "Based on the efficacy and safety of the drug in this trial, we believe that Hemopure could be an oxygen bridge to prevent permanent myocardial damage in patients sustaining a heart attack."

The COR-0002 trial is a single-blind, open-label, single-center, cross- over pilot study where subjects underwent coronary balloon occlusion, with and without oxygenated HBOC-201. The primary objective of the study was to test the hypothesis that intracoronary infusion of HBOC-201 during brief, total coronary artery occlusion would preserve left ventricular function. The primary endpoints in COR-0002 were left ventricular diastolic relaxation indices as assessed by left ventricular pressure-volume loops and ST segment changes as assessed via electrocardiograms.

The study concluded that HBOC-201 was indeed capable of preserving left ventricular function, likely through maintenance of myocardial oxygenation. According to the findings, the absence of coronary vasoconstriction, despite exposure to undiluted HBOC-201, further supports the potential utility of HBOC-201 in complicated patient subsets such as those with coronary artery disease. In addition, changes in electrocardiograms, indicating severe ischaemia during control coronary artery occlusions, were not present during or following HBOC-201 infusion. The report states that HBOC-201 did not cause any serious adverse event or significantly alter blood chemistry parameters through the 4-day follow-up period.

Based on the results, the authors hypothesized that, in an acute setting, HBOC-201 could serve as an oxygen bridge to reperfusion by percutaneous coronary intervention, extending the "golden" time period during which permanent myocardial damage is unlikely. The report noted that further studies will be required to determine whether HBOC-201 can enhance treatment efficacy in more complicated patient populations. The report concluded that this trial represents an important next step in the clinical development program for this product as a treatment for acute myocardial ischaemia.

Biopure Corporation

Biopure Corporation develops, manufactures and markets pharmaceuticals, called oxygen therapeutics, that are intravenously administered to deliver oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer - 250 (bovine)], or HBOC-201, is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic. The company is developing Hemopure for other indications and is supporting the U.S. Navy's government- funded efforts to develop a potential out-of-hospital trauma indication. Biopure's veterinary product Oxyglobin(R) [hemoglobin glutamer - 200 (bovine)], or HBOC-301, the only oxygen therapeutic approved for marketing by both the U.S. Food and Drug Administration and the European Commission, is indicated for the treatment of anemia in dogs. Biopure has sold approximately 200,000 units of Oxyglobin since its launch in 1998.

Contact: Tiana Gorham

Biopure Corporation

(617) 234-6826

IR@biopure.com


'/>"/>
SOURCE Biopure Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Biopure Reports on Meeting with the FDA
2. Biopure Announces 2007 Third Quarter Financial Results
3. Biopure Seeks Compassionate Use Protocol for Treatment of Acute Anemia
4. Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization
5. Kosan Announces Data Presentations at ASCO 2008 Annual Meeting
6. XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting
7. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
8. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
9. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
10. CryoLife Announces First Implant of Combination Aortic-Mitral Allograft Heart Valve at the Cleveland Clinic
11. Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... The global peripheral I.V. catheter market accounted for $3,702.2 ... grow at a CAGR of 6.0% during 2016-2022. The ... in the global market between the two types in ... segment accounted for the highest share in the global ... catheter market is witnessing high growth rate, due to ...
(Date:1/24/2017)... CHICAGO , January 23, 2017 ... solutions for life sciences, announces agClinical 3.3, the latest ... release further enables life science organizations to confidently and ... monitoring and better manage the electronic trial master file ... ...
(Date:1/23/2017)... , Jan. 23, 2017  HOPE BIOSCIENCES announced ... to develop and commercialize nuc -gemcitabine™ (APTA-12/HOPE-888) ... Korean pharmaceutical company. nuc -Gemcitabine ... against surface nucleolin found on many cancer cells, ... ADCs (antibody drug conjugates) or SMDCs (small molecule ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 23, 2017 , ... Texas Home Health, an ... two personal care service companies: Padre Home Health in Corpus Christi, Texas, and ... , Well regarded in their respective markets, these two agencies align with Texas ...
(Date:1/24/2017)... Clara, CA (PRWEB) , ... January 23, 2017 ... ... announces the launch of a new plugin that allows sleep centers to automatically ... Sleep Device Interface (SDI)—is a thin client browser plugin is quickly installed on ...
(Date:1/23/2017)... ... January 23, 2017 , ... PKF O’Connor Davies ... J. Nelson, a senior accountant at the Firm, will participate in the 40th Annual ... Over 200 runners will race up 1,576 steps, a vertical distance equal to about ...
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... the highly acclaimed series, Innovations with Ed Begley, Jr., scheduled to broadcast Saturday, ... technology behind SmartCap, which was founded in 2008 to address the limitations of ...
(Date:1/23/2017)... ... January 23, 2017 , ... The Masters ... management and evaluation leaders with decades of experience who remain current practitioners in ... States healthcare system, there is a renewed demand for versatile, data-driven leadership.The American ...
Breaking Medicine News(10 mins):